Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy.

Abstract

A patient with Hodgkin's disease (HD) underwent autologous bone marrow transplantation (ABMT). Six months later while receiving interleukin (IL)-2 and alpha-interferon immunotherapy, he developed a painful lesion in his oral cavity with a fistula in the buccal area. Excision biopsy disclosed necrotizing granulomatous inflammation with acid-fast bacillus. The patient received a 9-month course of isoniazide, rifampin and pyrazinamide, and recovered. The possible pathophysiological mechanism is discussed.

• Authors: A Toren, A Ackerstein, D Gazit, R Or, D Raveh, U Kupolovicz, D Engelhard, A Nagler
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 18 Issue 1 Pg. 209-10 (Jul 1996) ISSN: 0268-3369 [Print] England
• PMID: 8832017 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Anti-Bacterial Agents
• Antitubercular Agents
• Interferon-alpha
• Interleukin-2
• Recombinant Proteins
• Pyrazinamide
• Isoniazid
• Rifampin

Topics

• Adjuvants, Immunologic (adverse effects, therapeutic use)
• Adult
• Anti-Bacterial Agents
• Antitubercular Agents (therapeutic use)
• Bone Marrow Transplantation
• Combined Modality Therapy
• Disease Susceptibility
• Drug Therapy, Combination (therapeutic use)
• Fistula (etiology)
• Hodgkin Disease (complications, therapy)
• Humans
• Immunocompromised Host
• Interferon-alpha (adverse effects, therapeutic use)
• Interleukin-2 (adverse effects, therapeutic use)
• Isoniazid (therapeutic use)
• Male
• Opportunistic Infections (etiology)
• Oral Ulcer (etiology)
• Pyrazinamide (therapeutic use)
• Recombinant Proteins (adverse effects, therapeutic use)
• Rifampin (therapeutic use)
• Risk Factors
• Transplantation Conditioning (adverse effects)
• Transplantation, Autologous
• Tuberculosis, Oral (drug therapy, etiology)